Sialorrhea

Approved for this indication (2)

• glycopyrronium
• atropine

Phase 3 trials (2)

• rimabotulinumtoxinB
• incobotulinumtoxinA

Phase 2 trials (7)

• ipratropium
• oxybutynin
• scopolamine
• clonidine
• tropicamide
• wuling san
• suo quan wan

Other trials (2)

• clozapine
• sodium chloride

Organization Involved with Phase 3 Indications (14)

• Shionogi
• Allergan
• Merz
• University of Kansas
• University of Malaya
• US WorldMeds
• KPJ Tawakkal Health Centre
• University of Lyon
• Technion University
• Universidad Autonoma de Barcelona
• Ben Gurion University
• University of Texas, San Antonio
• ALS Association
• Carolinas MDA Neuromuscular/ALS Center-Carolinas Medical System

Organization Involved with Phase 2 Indications (14)

• Solstice Neurosciences
• NeuroHealing Pharmaceuticals Inc.
• Orient Pharma Co., Ltd.
• Michael J. Fox Foundation for Parkinson's Research
• Harvard University
• Mersey Care NHS Trust
• University of Manchester
• University of Ottawa
• Taichung Veterans General Hospital
• University of Buenos Aires
• Lancashire Teaching Hospitals NHS Foundation Trust
• Quest Research Institute
• University of Western Ontario
• University of Central Lancashire

Organization Involved with Other Experimental Indications (4)

• University of Toronto
• National Taiwan University
• Government of Taiwan
• The University of Texas, Dallas